Preparation and clinical utility of antihuman lymphocyte microsome gamma-globulin.
To eliminate side effects inherent to the administration of the presently available antilymphocyte serum (ALS), microsomal fractions of lymphocytes have used as the antigen. Antiserum produced using microsomal fraction from mouse thymus cell as the antigen proved to have potent immunosuppressive activity. Subsequently, microsomal fraction from cultured human lymphocytes was used to produce potent immunosuppressive antisera. The antisera thus prepared was found to have a high leucoagglutinin titer. The antihuman lymphocyte microsome gamma-globulin (AHLMG) prepared was administered to 6 patients undergoing renal transplantation from living donors. Severe rejection episodes and serious side effects such as anaphylactoid reaction and thrombocytopenia were nil. This AHLMG which is devoid of side effects yet retains immunosuppressive activity warrants extended purification.
D000293:Adolescent; D000328:Adult; D000818:Animals; D000961:Antilymphocyte Serum / Q000302:isolation & purification / Q000494:pharmacology*; D005069:Evaluation Studies as Topic; D005260:Female; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D016030:Kidney Transplantation; D008207:Lymphatic Metastasis; D008297:Male; D008861:Microsomes / Q000276:immunology*; D051381:Rats; D012510:Sarcoma 180 / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology* / Q000648:ultrastructure
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents